Dr. Apolo on Side Effects of Cabozantinib Plus Immunotherapy Agents in Bladder Cancer

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

In the combination of cabozantinib plus nivolumab (Opdivo) and cabozantinib plus ipilimumab (Yervoy), the typical side effects of each agent were shown. There was no synergy between the toxicities though, which is an encouraging sign, says Apolo.

The recommended phase II dose is cabozantinib at 40 mg (CHECK), nivolumab at 3 mg/kg, and ipilimumab at 1 mg/kg.